 Synaptogenix Inc NASDAQ: SNPX has announced an update on its ongoing National Institutes of Health NIH sponsored Phase 2b trial of Bryostatin-1 for moderately severe Alzheimers disease AD. To date, the Company has dosed 58 of its target 100 patients. 